Search

Your search keyword '"Dohner H"' showing total 168 results
Start Over Author "Dohner H"
168 results on '"Dohner H"'

51. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia

Author

Skogsberg, A., Tobin, G., Krober, A., Kienle, D., Thunberg, U., Aleskog, A., Karlsson, K., Laurell, A., Merup, M., Vilpo, J., Sundstrom, C., Roos, G., Jernberg-Wiklund, H., Dohner, H., Nilsson, K., Stilgenbauer, S., Rosenquist, R., Skogsberg, A., Tobin, G., Krober, A., Kienle, D., Thunberg, U., Aleskog, A., Karlsson, K., Laurell, A., Merup, M., Vilpo, J., Sundstrom, C., Roos, G., Jernberg-Wiklund, H., Dohner, H., Nilsson, K., Stilgenbauer, S., and Rosenquist, R.

Abstract

The G(-248)A polymorphism in the promoter region of the Bax gene was recently associated with low Bax expression, more advanced stage, treatment resistance and short overall survival in B-cell chronic lymphocytic leukemia (CLL), the latter particularly in treated patients. To investigate this further, we analyzed 463 CLL patients regarding the presence or absence of the G(-248)A polymorphism and correlated with overall survival, treatment status and known prognostic factors, for example, Binet stage, VH mutation status and genomic aberrations. In this material, similar allele and genotype frequencies of the Bax polymorphism were demonstrated in CLL patients and controls (n=207), where 19 and 21% carried this polymorphism, respectively, and no skewed distribution of the polymorphism was evident between different Binet stages and VH mutated and unmutated CLLs. Furthermore, no difference in overall survival was shown between patients displaying the G(-248)A polymorphism or not (median survival 85 and 102 months, respectively, P=0.21), and the polymorphism did not influence outcome specifically in treated CLL. Neither did the polymorphism affect outcome in prognostic subsets defined by VH mutation status or genomic aberrations. In conclusion, the pathogenic role and clinical impact of the Bax polymorphism is limited in CLL. © 2006 Nature Publishing Group All rights reserved.

Published
2006
Full Text
View/download PDF

52. Strikingly homologous immunoglobulin gene rearrangements and poor outcome inV(H)3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status

Author

Thorselius, M, Krober, A, Murray, F, Thunberg, U, Tobin, G, Buhler, A, Kienle, D, Albesiano, E, Maffei, R, Dao-Ung, LP, Wiley, J, Vilpo, J, Laurell, A, Merup, M, Roos, G, Karlsson, K, Chiorazzi, N, Marasca, R, Dohner, H, Stilgenbauer, S, Rosenquist, R, Thorselius, M, Krober, A, Murray, F, Thunberg, U, Tobin, G, Buhler, A, Kienle, D, Albesiano, E, Maffei, R, Dao-Ung, LP, Wiley, J, Vilpo, J, Laurell, A, Merup, M, Roos, G, Karlsson, K, Chiorazzi, N, Marasca, R, Dohner, H, Stilgenbauer, S, and Rosenquist, R

Abstract

We recently reported that Swedish V(H)3-21-using chronic lymphocytic leukemia (CLL) patients showed restricted immunoglobulin gene features and poor prognosis despite V-H mutation status. To investigate this further, we analyzed the V-H and V-L gene rearrangements in 90 V(H)3-21(+) patients from Sweden, Germany, Italy, United States, Finland, and Australia and correlated these data with survival and other prognostic markers. Sixty-three percent exhibited mutated V-H genes and 37% unmutated V-H genes. Fifty (56%) patients displayed a short and homologous heavy-chain CDR3, many of these with the amino acid motif DANGMDV. Also, a highly biased V(lambda)2-14 use was evident in 72% of patients with a restricted light-chain CDR3, QVWDS(S/G)SDHPWV. Combined restricted heavy- and light-chain CDR3s were found in patients from all included countries. Although V(H)3-21(+) CLILs have a remarkably predominant X expression, analyses of kappa deleting element indicated a conserved light-chain rearrangement order. The overall survival was poor in the V(H)3-21(+) cohort (median survival, 88 months), with no significant difference in relation to mutation status or CDR3 homology. High ZAP-70 and CD38 expression was found in both mutated and unmutated VH3-21(+) cases as well as a slight increase of 11q- aberrations. In summary, highly restricted B-cell receptors and worse outcome characterize VH3-21(+) CLLs independent of geographic origin and mutation status.

Published
2006
Full Text
View/download PDF

54. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Author

Lubbert, M., primary, Ruter, B. H., additional, Claus, R., additional, Schmoor, C., additional, Schmid, M., additional, Germing, U., additional, Kuendgen, A., additional, Rethwisch, V., additional, Ganser, A., additional, Platzbecker, U., additional, Galm, O., additional, Brugger, W., additional, Heil, G., additional, Hackanson, B., additional, Deschler, B., additional, Dohner, K., additional, Hagemeijer, A., additional, Wijermans, P. W., additional, and Dohner, H., additional

Published
2011
Full Text
View/download PDF

55. Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia

Author

Russ, A. C., primary, Sander, S., additional, Luck, S. C., additional, Lang, K. M., additional, Bauer, M., additional, Rucker, F. G., additional, Kestler, H. A., additional, Schlenk, R. F., additional, Dohner, H., additional, Holzmann, K., additional, Dohner, K., additional, and Bullinger, L., additional

Published
2011
Full Text
View/download PDF

57. Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk

Author

Winkler, D., primary, Schneider, C., additional, Zucknick, M., additional, Bogelein, D., additional, Schulze, K., additional, Zenz, T., additional, Mohr, J., additional, Philippen, A., additional, Huber, H., additional, Buhler, A., additional, Habermann, A., additional, Benner, A., additional, Dohner, H., additional, Stilgenbauer, S., additional, and Mertens, D., additional

Published
2010
Full Text
View/download PDF

63. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Author

Liso, A., primary, Castiglione, F., additional, Cappuccio, A., additional, Stracci, F., additional, Schlenk, R. F., additional, Amadori, S., additional, Thiede, C., additional, Schnittger, S., additional, Valk, P. J.M., additional, Dohner, K., additional, Martelli, M. F., additional, Schaich, M., additional, Krauter, J., additional, Ganser, A., additional, Martelli, M. P., additional, Bolli, N., additional, Lowenberg, B., additional, Haferlach, T., additional, Ehninger, G., additional, Mandelli, F., additional, Dohner, H., additional, Michor, F., additional, and Falini, B., additional

Published
2008
Full Text
View/download PDF

65. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations

Author

Sander, S., primary, Bullinger, L., additional, Leupolt, E., additional, Benner, A., additional, Kienle, D., additional, Katzenberger, T., additional, Kalla, J., additional, Ott, G., additional, Muller-Hermelink, H. K., additional, Barth, T. F.E., additional, Moller, P., additional, Lichter, P., additional, Dohner, H., additional, and Stilgenbauer, S., additional

Published
2008
Full Text
View/download PDF

71. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup

Author

Schaich, M., primary, Schlenk, R. F., additional, Al-Ali, H. K., additional, Dohner, H., additional, Ganser, A., additional, Heil, G., additional, Illmer, T., additional, Krahl, R., additional, Krauter, J., additional, Sauerland, C., additional, Buchner, T., additional, and Ehninger, G., additional

Published
2007
Full Text
View/download PDF

74. Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

Author

Heidel, F., primary, Cortes, J., additional, Ruecker, F., additional, Kaufmann, M., additional, Aulitzky, W., additional, Letvak, L., additional, Kindler, T., additional, Huber, C., additional, Dohner, H., additional, Kantarjian, H., additional, and Fischer, T., additional

Published
2005
Full Text
View/download PDF

75. P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS

Author

Kuendgen, A., primary, Schmid, M., additional, Knipp, S., additional, Hildebrandt, B., additional, Fox, F., additional, Strupp, C., additional, Steidl, C., additional, Haas, R., additional, Germing, U., additional, Dohner, H., additional, and Gattermann, N., additional

Published
2005
Full Text
View/download PDF

81. Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group

Author

Dohner, H., primary, Ho, A. D., additional, Thaler, J., additional, Stryckmans, P., additional, Sonneveld, P., additional, Witte, T. d., additional, Lechner, K., additional, Lauria, F., additional, Bodewadt-Radzun, S., additional, Suciu, S., additional, Solbu, G., additional, Witt, B., additional, Hunstein, W., additional, and Zittoun, R., additional

Published
1993
Full Text
View/download PDF

84. Genetics of chronic lymphocytic leukemia: genomic aberrations and V[subH] gene mutations status in pathogenesis and clinical course.

Author

Stilgenbauer, S., Bullinger, L., Lichter, P., and Dohner, H.

Subjects
CHRONIC lymphocytic leukemia, GENETIC disorders
Abstract

There is increasing evidence that a subset of chronic lymphocytic leukemia is caused by an inherited predisposition. Here we review the evidence for an inherited predisposition, the characteristics of familial cases and evidence for the involvement of specific genes. [ABSTRACT FROM AUTHOR]

Published
2002

85. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

Author

Schlenk, R.F., Hartmann, F., Hensel, M., Jung, W., Weber-Nordt, R., Gabler, A., Haas, R., Ho, A.D., Trumper, L., and Dohner, H.

Subjects
LEUKEMIA treatment, STEM cell transplantation
Abstract

Studies less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on the study of leukemia.

Published
2002
Full Text
View/download PDF

86. Acute myeloid leukaemia

Author

Estey, E. and Dohner, H.

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults. The median age at presentation for patients with AML is 70 years. In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease. Genetic defects are thought to be the most important factors in determining the response to chemotherapy and outcome. Whereas significant progress has been made in the treatment of younger adults, the prospects for elderly patients have remained dismal, with median survival times of only a few months. This difference is related to comorbidities associated with ageing and to disease biology. Current efforts in clinical research focus on the assessment of targeted therapies. Such new approaches will probably lead to an increase in the cure rate.

Published
2006
Full Text
View/download PDF

89. European Silver Paper on the future of health promotion and preventive actions, basic research and clinical aspects of age-related diseases

Author

Cruz-Jentoft, A. J., Franco, A., Sommer, P., Baeyens, J. -P, Jankowska, E., Maggi, A., Ponikowski, P., Ryś, A., Szczerbińska, K., Milewicz, A., Andersen-Ranberg, K., Benvenuti, F., Bien, B., Błȩdowski, P., Buján, J., Büla, C., Bürkle, A., Cherubini, A., Crepaldi, G., Man, F., Dohner, H., Dunn-Walters, D., Finne-Soveri, H., Grodzicki, T., Jansen-Dürr, P., Kostka, T., Kuźnicki, J., Lisowski, J., Lunenfeld, B., Maggi, S., Michel, J. -P, Millard, P., Perek-Bialas, J., Petridou, E., Pirags, V., Rymaszewska, J., Kiejna, A., Skelton, D., Sławek, J., Spławinski, J., Suominen, M., Nektarios Tavernarakis, Todd, C., Topinkova, E., Tworowska-Bardzińska, U., Wieczorowska-Tobis, K., Wuttke, W., Zatoński, W., Kopacz, E., Schröder, K. T., Joksts, R., Hellerova, M., Buzek, J., Belohorska, I., Linell, A., Lidbrink, M., Granberg, A. -K, Agrotou, A., Angelidou, E. I., Georgescu, D., Szilágyi, A., Kluczynski, P., Macke-Nauman, A., Antonowicz-Juchniewicz, J., Bar-Andziak, E., Nauman, J., Sowiński, J., Bednarek-Tupikowska, G., Bilińska, M., Bolanowski, M., Dragan, S., Karbownik-Lewińska, M., Kobylarek, A., Kołodziej, J., Kornafel, J., Kos-Kudła, B., Krzyanowska-Świniarska, B., Andrzejak, R., Lewiński, A., Łomna-Bogdanov, E., and Machaj, Z.

91. The European Hematology Association Roadmap for European Hematology Research: a consensus document

Author

Cordonnier, C., Dohner, H., Engert, A., Schuringa, J. J., Eichinger, S., Green, T., Salles, G., De Haas, F., Brand, A., EHA, Roadmap For European Hematology Research, Coiffier, B., Jaffredo, T., Fibbe, W., De Wit, T. D., Iolascon, A., Balduini, C., and Rodeghiero, F.

Subjects
610 Medicine & health, 3. Good health
Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at Euro 23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine sections in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients. Received December 15, 2015. Accepted January 27, 2016. Copyright © 2016, Ferrata Storti Foundation

92. A Universal Predictor of Drug Response

Author

Steen Knudsen, Jesper Dahlgaard, Jensen, T., Timmons, J., Bullilnger, J., Schlenk, R., Dohner, H., Metzeler, K., Bohlander, S., Buske, C., Hiddemann, W., Martin Bøgsted, Karen Dybkaer, Hans Erik Johnsen, and Mette Nyegaard

93. European Silver Paper on the future of health promotion and preventive actions, basic research and clinical aspects of age-related diseases

Author

Cruz-Jentoft, A. J., Franco, A., Sommer, P., Baeyens, J. -P, Jankowska, E., Maggi, A., Ponikowski, P., Ry, A., Szczerbi Ska, K., Milewicz, A., Andersen-Ranberg, K., Benvenuti, F., Bien, B., B Dowski, P., Bujn, J., Quot, B., U La, C., U Rkle, A., Cherubini, A., Crepaldi, G., Man, F., Dohner, H., Dunn-Walters, D., Finne-Soveri, H., Grodzicki, T., Jansen-D{\&quot, U Rr, P., Kostka, T., Ku Nicki, J., Lisowski, J., Lunenfeld, B., Maggi, S., Michel, J. -P, Millard, P., Perek-Bialas, J., Petridou, E., Pirags, V., Rymaszewska, J., Kiejna, A., Skelton, D., S Awek, J., Sp Awinski, J., Suominen, M., Nektarios Tavernarakis, Todd, C., Topinkova, E., Tworowska-Bardzi Ska, U., Wieczorowska-Tobis, K., Wuttke, W., Zato Ski, W., Kopacz, E., Schr{\&quot, O, K. T., Joksts, R., Hellerova, M., Buzek, J., Belohorska, I., Linell, A., Lidbrink, M., Granberg, A. -K, Agrotou, A., Angelidou, E. I., Georgescu, D., Szilgyi, A., Kluczynski, P., Macke-Nauman, A., Antonowicz-Juchniewicz, J., Bar-Andziak, E., Nauman, J., Sowi Ski, J., Bednarek-Tupikowska, G., Bili Ska, M., Bolanowski, M., Dragan, S., Karbownik-Lewi Ska, M., Kobylarek, A., Ko Odziej, J., Kornafel, J., Kos-Kud A, B., Krzyanowska- Winiarska, B., Andrzejak, R., Lewi Ski, A., Omna-Bogdanov, E., and Machaj, Z.

94. European Silver Paper on the future of health promotion and preventive actions, basic research and clinical aspects of age-related diseases

Author

Cruz-Jentoft, A. J., Franco, A., Sommer, P., Baeyens, J. -P, Jankowska, E., Maggi, A., Ponikowski, P., Ry, A., Szczerbi Ska, K., Milewicz, A., Andersen-Ranberg, K., Benvenuti, F., Bien, B., B Dowski, P., Bujn, J., Amp, B., quot, U La, C., U Rkle, A., Cherubini, A., Crepaldi, G., Man, F., Dohner, H., Dunn-Walters, D., Finne-Soveri, H., Grodzicki, T., Jansen-D{&amp, U Rr, P., Kostka, T., Ku Nicki, J., Lisowski, J., Lunenfeld, B., Maggi, S., Michel, J. -P, Millard, P., Perek-Bialas, J., Petridou, E., Pirags, V., Rymaszewska, J., Kiejna, A., Skelton, D., S Awek, J., Sp Awinski, J., Suominen, M., Nektarios Tavernarakis, Todd, C., Topinkova, E., Tworowska-Bardzi Ska, U., Wieczorowska-Tobis, K., Wuttke, W., Zato Ski, W., Kopacz, E., Schr{&amp, O, K. T., Joksts, R., Hellerova, M., Buzek, J., Belohorska, I., Linell, A., Lidbrink, M., Granberg, A. -K, Agrotou, A., Angelidou, E. I., Georgescu, D., Szilgyi, A., Kluczynski, P., Macke-Nauman, A., Antonowicz-Juchniewicz, J., Bar-Andziak, E., Nauman, J., Sowi Ski, J., Bednarek-Tupikowska, G., Bili Ska, M., Bolanowski, M., Dragan, S., Karbownik-Lewi Ska, M., Kobylarek, A., Ko Odziej, J., Kornafel, J., Kos-Kud A, B., Krzyanowska- Winiarska, B., Andrzejak, R., Lewi Ski, A., Omna-Bogdanov, E., and Machaj, Z.

96. Dendritic cells for autologous tumor vaccination in chronic myeloid leukemia

Author

Westermann, J., Aicher, A., Qin, Z., Daemen, K., Mapara, M., Dohner, H., Blankenstein, Th., Dorken, B., and Pezzutto, A.

Subjects
Chronic myeloid leukemia -- Research, Antigen presenting cells -- Research, Cancer vaccines -- Research, Health, Research
Abstract

'Dendritic Cells for Autologous Tumor Vaccination in Chronic Myeloid Leukemia.' J. Westermann, A. Aicher, Z. Qin, K. Daemen, M. Mapara, H. Dohner, Th. Blankenstein, B. Dorken and A. Pezzutto. Department [...]

Published
1997

97. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

Author

Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbaur, S., Volkmann, M., Galle, P.R., Poustka, A., Hunstein, W., and Lichter, P.

Subjects
Complications and side effects, Genetic aspects, Chromosome deletion -- Complications and side effects -- Genetic aspects, Chronic lymphocytic leukemia -- Genetic aspects -- Complications and side effects
Abstract

According to the authors' abstract of an article published in Blood, 'Conventional cytogenetic analysis in B-cell chronic lymphocytic leukemia (B-CLL) has been very difficult, and the prognostic significance of specific [...]

Published
1995

98. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group

Author

Kirsten Fischer, Barbara Eichhorst, Richard Rosenquist, Hartmut Döhner, Kostas Stamatopoulos, Paolo Ghia, Eugen Tausch, Michael Hallek, Sonia Jaramillo, Valentin Goede, Manuela Hoechstetter, Sandra Robrecht, Andreas Agathangelidis, Johannes Bloehdorn, Christof Schneider, Stephan Stilgenbauer, Jasmin Bahlo, Jaramillo, S., Agathangelidis, A., Schneider, C., Bahlo, J., Robrecht, S., Tausch, E., Bloehdorn, J., Hoechstetter, M., Fischer, K., Eichhorst, B., Goede, V., Hallek, M., Dohner, H., Rosenquist, R., Ghia, P., Stamatopoulos, K., and Stilgenbauer, S.

Subjects
Oncology, medicine.medical_specialty, Chronic lymphocytic leukemia, Article, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, Internal medicine, hemic and lymphatic diseases, Medicine, Humans, Chronic Lymphocytic Leukemia, Stereotyped subset, Prospective Studies, Prospective cohort study, Retrospective Studies, business.industry, Retrospective cohort study, Hematology, medicine.disease, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Clinical trial, Leukemia, 030220 oncology & carcinogenesis, Cohort, Mutation, business, IGHV@, Immunoglobulin Heavy Chains, 030215 immunology
Abstract

Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B-cell receptor immunoglobulins (BcR IG) and can be assigned to distinct subsets, each with a particular BcR IG. The largest stereotyped subsets are #1, #2, #4 and #8, associated with specific clinico-biological characteristics and outcomes in retrospective studies. We assessed the associations and prognostic value of these BcR IG in prospective multicenter clinical trials reflective of two different clinical situations: (i) early-stage patients ('watch and wait' arm of the CLL1 trial) (n=592); (ii) patients in need of treatment, enrolled in three phase III trials (CLL8, CLL10, CLL11), treated with different chemo-immunotherapies (n=1,861). Subset #1 was associated with del(11q), higher CLL International Prognostic Index (CLL-IPI) scores and similar clinical course to CLL with unmutated immunoglobulin heavy variable (IGHV) genes (U-CLL) in both early and advanced stage groups. IGHV-mutated (M-CLL) subset #2 cases had shorter time-to-first-treatment (TTFT) versus other M-CLL cases in the early-stage cohort (hazard ratio [HR]: 4.2, confidence interval [CI]: 2-8.6, P

Published
2020

99. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

Author

Marco Sborgia, Marco Vignetti, Massimo Breccia, Fabio Efficace, Roberto Cairoli, Hartmut Link, Uwe Platzbecker, Norbert Schmitz, Ombretta Annibali, Agostino Cortelezzi, Francesca Paoloni, Eros Di Bona, Nicola Di Renzo, Alfonso Maria D'Arco, Lorella Melillo, Francesco Lo-Coco, Peter Brossart, Felicetto Ferrara, Chiara Frairia, Franco Mandelli, Christoph Röllig, Laura Cicconi, Claudio Fozza, Konstanze Döhner, Walter Fiedler, Bernd Hertenstein, Francesco Fabbiano, Richard F. Schlenk, Mariadomenica Divona, Francesco Albano, Mohammed Wattad, Maria Teresa Voso, Christian Thiede, Christian Brandts, Paola Fazi, Gerhard Ehninger, Mathias Hänel, Sergio Amadori, Alessandro Rambaldi, Giorgio La Nasa, Helmut R. Salih, Hartmut Döhner, Michael Lübbert, Giuseppe Avvisati, Arnold Ganser, Erika Borlenghi, Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, and Lo-Coco, F

Subjects
Adult, Male, Oncology, Acute promyelocytic leukemia, Cancer Research, medicine.medical_specialty, Adolescent, Retinoic acid, Tretinoin, Follow-Up Studie, law.invention, Young Adult, chemistry.chemical_compound, Leukemia, Promyelocytic, Acute, Randomized controlled trial, law, Germany, Internal medicine, medicine, acute leukemia, Arsenic trioxide, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, All trans, Hematology, Long term results, Middle Aged, APL, arsenic trioxide, medicine.disease, Clinical trial, Prospective Studie, Leukemia, Treatment Outcome, Italy, chemistry, Female, business, Settore MED/15 - Malattie del Sangue, Human
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results